Fireside Chat with Peter F. Lebowitz, MD, PhD, Global Oncology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson
As Global Oncology Therapeutic Area Head for the Janssen Pharmaceutical Companies of Johnson & Johnson, Peter F. Lebowitz, M.D., Ph.D. is responsible for end-to-end discovery, development and life cycle advancement of the company’s robust oncology pipeline and portfolio. He leads a global team of scientists that bring together expertise in small molecules, advanced biologics, cell therapies, vaccine platforms, translational research, diagnostics, and immuno-oncology. Under Peter’s leadership, Janssen Oncology has achieved many noteworthy milestones including seven major product approvals in the last eight years for such first-in-class therapies as IMBRUVICA® (ibrutinib), DARZALEX® (daratumumab) and ERLEADA® (apalutamide); seven U.S. Food and Drug Administration Breakthrough Therapy Designations; and tremendous, rapid growth within the group’s early development portfolio.
With a strategy focused on driving towards transformational therapies, Peter also successfully established an external innovation strategy to advance science and novel therapeutics in core disease areas, including hematologic malignancies, prostate cancer, immuno-oncology, and lung cancer. The combination of these efforts has led to more than 80 strategic oncology partnerships across the life sciences ecosystem and continues to distinguish Janssen as an industry leader and global oncology innovator.
Prior to his appointment as Global Oncology Therapeutic Area Head, Peter served as the Hematologic Malignancy Disease Area Leader within Janssen Research & Development. In this role, he had responsibility for creating and executing the scientific strategy to advance internal and externally-sourced discovery and development programs. Together with his team, Peter is recognized for building an industry-leading hematologic malignancy portfolio that has been foundational for scientific innovation and has progressed important therapeutics that have transformed patient care.
Before joining Janssen R&D, Peter held Vice President positions in Discovery and Early/Latestage Clinical Development for GlaxoSmithKline where he successfully filed 10 Investigational New Drug applications and played a significant role in the global registration of three oncology medicines. During his tenure, he also directly led major programs from preclinical discovery through pivotal Phase 3 registration trials.
Prior to transitioning to the pharmaceutical industry, Peter served as an Assistant Professor of Medicine, Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. There he established an independently funded translational and clinical research program and led numerous clinical research programs as a principal investigator. He also had the privilege of caring for many oncology patients during this time. Peter graduated magna cum laude from Harvard University, holds a master’s degree in Health Care Policy from Oxford University, and earned his medical degree and doctorate from the University of Pennsylvania School of Medicine. He completed his postgraduate clinical training in Internal Medicine at Duke University Medical Center and his Hematology/Oncology fellowship at the National Cancer Institute, National Institutes of Health. He has been board certified in Internal Medicine and Medical Oncology.